Med-tech company a2z Radiology AI can now stake its claim as a leader in abdomen-pelvis AI. 

The company has secured US FDA clearance for a first-of-its-kind device -- a2z-Unified-Triage -- that flags and prioritizes seven urgent findings on abdomen-pelvis CT scans simultaneously. 

The system delivers a single-pass triage for seven high-consequence acute conditions, a capability never before available in the U.S. market. 

Abdomen-pelvis CT is the nation’s highest-volume CT category, with more than 20 million exams conducted each year. As case volumes rise, a2z-Unified-Triage works to flag suspected emergencies and push them to the top of radiologists’ worklists within minutes, speeding care for critical patients. 

“We set out to build a generalist system that could scale across conditions,” said Pranav Rajpurkar, co-founder of a2z Radiology AI and Associate Professor at Harvard Medical School. “We are starting with high-consequence acute conditions, cases where rapid triage can have the greatest immediate impact on patient care.” 

The system covers seven major acute conditions in a single integration: small bowel obstruction, acute cholecystitis, acute pancreatitis, acute diverticulitis, hydronephrosis, free air, and unruptured abdominal aortic aneurysm. 

“For five of these seven conditions, we're bringing AI triage to the U.S. market for the first time. And we're not stopping at seven. There's still a lot of scaling ahead,” said Samir Rajpurkar, co-founder and CEO. 

a2z Radiology AI continues to build the intelligence layer for medical imaging, aiming to transform how radiologists prioritize and manage high-stakes cases.